https://orcid.org/0000-0003-1010-3997
References
- Balsa LM, Baran EJ, León IE. Copper complexes as antitumor agents: in vitro and in vivo evidences. Curr Med Chem. 2023;30:5. doi:10.2174/0929867328666211117094550
- Paprocka R, Wiese-Szadkowska M, Janciauskiene S, et al. Latest developments in metal complexes as anticancer agents. Coord Chem Rev. 2022;452:214307. doi:10.1016/j.ccr.2021.214307
- León IE, Cadavid-Vargas J, Di Virgilio AL, et al. Vanadium, Ruthenium and Copper compounds: a new class of non-platinum metal-based antitumor agents. Curr Med Chem. 2017;24:112–148. doi:10.2174/0929867323666160824162546
- Pratesi G, Perego P, Polizzi D, et al. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours hypersensitivity of p53-mutant human tumour xenografts. Br J Cancer. 1999;80:1912–1919. doi:10.1038/sj.bjc.6690620
- Lazarevic T, Rilak A, Bugarcic ZD. Platinum, palladium, gold and ruthenium complexes as anticancer agents: current clinical uses, cytotoxicity studies and future perspectives. Eur J Med Chem. 2017;142:8–31. doi:10.1016/j.ejmech.2017.04.007
- Beale P, Judson I, O'Donnell A, et al. A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473). Br J Cancer. 2003;88:1128–1134. doi:10.1038/sj.bjc.6600854
- Gelmon KA, Vandenberg TA, Panasci L, et al. A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: A National Cancer Institute of Canada Clinical Trials Group trial, IND 129. Ann Oncol. 2003;14:543–548. doi:10.1093/annonc/mdg171
- Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery and Pt(IV) prodrugs. Chem Rev. 2016;116:3436–3486. doi:10.1021/acs.chemrev.5b00597
- Sava G, Bergamo A, Zorzetb S, et al. Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A. Eur J Cancer. 2002;38(3):427–435. doi:10.1016/s0959-8049(01)00389-6
- Monro S, Colon KL, Yin H, et al. Transition metal complexes and photodynamic therapy from a tumor-centered approach: challenges, opportunities and highlights from the development of TLD1433. Chem Rev. 2019;119(2):797–828. doi:10.1021/acs.chemrev.8b00211
- Leijen S, Burgers SA, Baas P, et al. Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. Invest New Drugs. 2015;33(1):201–214. doi:10.1007/s10637-014-0179-1
- Spratlin J, O'Kane GM, Oh DY, et al. BOLD-100-001 (TRIO039): a phase 2 study of BOLD-100 in combination with FOLFOX in patients with advanced mCRC previously treated with FOLFOX/CAPOX-Efficacy and safety analysis. J Clin Oncol. 2024;42:3. doi:10.1200/JCO.2024.42.3_suppl.143
- Baier D, Schoenhacker-Alte B, Rusz M, et al. The anticancer ruthenium compound BOLD-100 targets glycolysis and generates a metabolic vulnerability towards glucose deprivation. Pharmaceutics. 2022;14:238. doi:10.3390/pharmaceutics14020238
- Balsa LM, Solernó LM, Rodriguez MR, et al. Cu(II)-acylhydrazone complex, a potent and selective antitumor agent against human osteosarcoma: mechanism of action studies over in vitro and in vivo cell models. Chem Biol Interact. 2023;384:110685. doi:10.1016/j.cbi.2023.110685
- Carcelli M, Tegoni M, Bartoli J, et al. In vitro and in vivo anticancer activity of tridentate thiosemicarbazone copper complexes: unravelling an unexplored pharmacological target. Eur J Med Chem. 2020;194:112266. doi:10.1016/j.ejmech.2020.112266
- Balsa LM, Rodriguez MR, Ferraresi-Curotto V, et al. Finding new molecular targets of two copper(II)-hydrazones complexes on triple negative breast cancer cells using mass spectrometry-based quantitative proteomics. Int J Mol Sci. 2023;24(8):7531. doi:10.3390/ijms24087531
- Aguilar-Jiménez Z, Espinoza-Guillén A, Resendiz-Acevedo K, et al. The importance of being Casiopeina as polypharmacologycal profile mixed chelate-copper (II) complexes and their in vitro and in vivo activities. Inorganics. 2023;11(10):394. doi:10.3390/inorganics11100394
- Crans DC, Henry L, Cardiff G, et al. Developing vanadium as an antidiabetic or anticancer drug: a clinical and historical perspective. Met Ions Life Sci. 2019;203–230. doi:10.1515/9783110527872-014
- Aureliano M, De Sousa-Coelho AL, Dolan CC, et al. Biological consequences of vanadium effects on formation of reactive oxygen species and lipid peroxidation. Int J Mol Sci. 2023;24(6):5382. doi:10.3390/ijms24065382
- Ferretti V, León IE. An overview of vanadium and cell signaling in potential cancer treatments inorganics. Inorganics. 2022;10:47. doi:10.3390/inorganics10040047